Literature DB >> 12897549

The impact of malignant disease on facial nerve function after parotidectomy.

Todd W Ellingson1, James I Cohen, Peter Andersen.   

Abstract

OBJECTIVES/HYPOTHESIS: Studies of immediate postoperative facial nerve function following parotidectomy focus on benign disease. The purpose of the study was to compare facial nerve function with regard to benign or malignant disease in patients undergoing superficial parotidectomy. STUDY
DESIGN: Retrospective cohort study of consecutive patients undergoing parotidectomy between 1995 to 2002.
METHODS: House-Brackmann (HB) grade was recorded or assigned at the first postoperative visit. For patients with HB grade of III or greater, final resolution of facial nerve function was recorded. A chi2 analysis for independence was conducted between patients with HB grade of II or less and those with HB grade of III or greater and final pathological finding (benign vs. malignant disease). Mean and median times to resolution were determined for patients with HB grade of III or greater. Times to resolution for benign and malignant disease for those with HB grade of III or greater were compared (Kaplan-Meier method).
RESULTS: Sixty-seven patients with benign disease and 52 with malignant disease were included. Ninety-four percent of patients with benign disease had HB grade of II or less at first postoperative visit (mean period, 11.6 d) compared with 76.9% of patients with malignant disease (mean period, 12.4 d). A chi2 analysis found this difference significant (chi2 = 7.36, P =.0067). Time to resolution for HB grade of III or greater was 253.8 days (+/-168.2 d) with median time of 229.5 days for benign disease and 182.4 days (+/-134.6 d) with median time of 138 days for malignant disease. Kaplan-Meier comparison found no significant differences in time to final resolution (P =.83). Three patients in the group with malignant disease had unresolved dysfunction (one patient for >2 y).
CONCLUSIONS: Patients with benign disease have a greater chance of having HB grade of II or less immediately following surgery; however, whether the disease is benign or malignant, long-term final facial nerve function is the same.

Entities:  

Mesh:

Year:  2003        PMID: 12897549     DOI: 10.1097/00005537-200308000-00006

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Autofluorescence spectroscopy for nerve-sparing laser surgery of the head and neck-the influence of laser-tissue interaction.

Authors:  Florian Stelzle; Maximilian Rohde; Max Riemann; Nicolai Oetter; Werner Adler; Katja Tangermann-Gerk; Michael Schmidt; Christian Knipfer
Journal:  Lasers Med Sci       Date:  2017-05-27       Impact factor: 3.161

2.  Major salivary gland diseases. Multicentre study.

Authors:  R Fiorella; V Di Nicola; M L Fiorella; D A Spinelli; F Coppola; P Luperto; L Madami
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-06       Impact factor: 2.124

3.  Nerve spectroscopy: understanding peripheral nerve autofluorescence through photodynamics.

Authors:  Fernando Dip; Rene Aleman; Mariano Socolovsky; Nerina Villalba; Jorge Falco; Emanuele Lo Menzo; Kevin P White; Raul J Rosenthal
Journal:  Surg Endosc       Date:  2021-03-29       Impact factor: 4.584

Review 4.  Contemporary management of tumors of the salivary glands.

Authors:  Joseph M Scianna; Guy J Petruzzelli
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

5.  Clinical outcomes of bulky parotid gland cancers: need for self-examination and screening program for early diagnosis of parotid tumors.

Authors:  Sung Yong Choi; Eunkyu Lee; Eunhye Kim; Man Ki Chung; Young-Ik Son; Chung-Hwan Baek; Han-Sin Jeong
Journal:  BMC Cancer       Date:  2021-02-18       Impact factor: 4.430

6.  Facial paralysis after superficial parotidectomy: analysis of possible predictors of this complication.

Authors:  Renato Fortes Bittar; Homero Penha Ferraro; Marcelo Haddad Ribas; Carlos Neutzling Lehn
Journal:  Braz J Otorhinolaryngol       Date:  2015-12-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.